STAAR's China boom and buyback lift it, but guidance silence and insurance fears weigh
No second-half guidance spooks investors STAAR beat second-quarter sales estimates, yet management gave no guidance for the rest of the year and stayed cautious. Analysts said investors want that clarity before buying, and the stock fell about 10% — the drop is about uncertainty, not weak sales.
Explains the sharp negative reaction despite a sales beat, a key force behind the stock's move.
Insurance changes threaten US procedure volumes Intuitive Surgical warned that changes to some insurance plans could slow US procedures, dragging medical device stocks down together. Fewer covered procedures means fewer people getting STAAR's lens implants, so the whole sector — including STAAR — sold off on demand worries.
Shows an industry-wide demand headwind that pushed STAA down alongside peers.
China sales more than double, swinging STAAR to profit STAAR posted $8.1 million net income versus a year-earlier loss, with sales up 111% to $93.5 million. China revenue more than doubled to $52.3 million on the new EVO+ lens, lifting volumes and prices. Management cautioned the growth compares against an unusually weak prior year.
The core fundamental driver: real profit and booming China demand that support the stock.
$50M buyback signals confidence and supports the stock STAAR's board approved buying back up to $50 million of stock over 12 months, roughly 5% of shares, funded from cash and free cash flow. With no debt and $181.5 million in cash, this returns money to shareholders and can lift the share price.
A concrete capital action that directly supports STAA's share price.